The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza, ⁠the company ⁠said on M...

Novartis is significantly expanding its biomedical research and drug development operations in India, positioning it as a key global hub ou...

The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma...

Novartis is acquiring U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash to expand its rare disease treatment port...

Recent GST rate cuts on critical medicines are set to significantly reduce costs for treatments of conditions like multiple myeloma, lung c...

ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ...

The high cost of Zolgensma, a one-time gene therapy used to treat spinal muscular atrophy (SMA) in children under two, is to limited patien...

The recent GST exemption on medicines for rare diseases in India is unlikely to help many patients as the drugs are still too expensive, sa...

The Basel-based company, which makes a vast array of drugs including cancer treatment Gleevec and Diovan for hypertension, says it wants to...

Swiss drugmaker Novartis is turning to tech to deal with the pharma business in times of pandemic, as companies go virtual. Bertrand Bodson...

In the absence of sustained investments by government, the cure for epidemics such as Covid-19 becomes a challenge, Novartis global CEO Vas...

Novartis is one of the oldest pharma MNCs known for anti-cancer and anti-diabetic drugs. Despite the patent expiry for its popular anti-dia...

Novartis will cut about 2,200 jobs in Switzerland over the next four years as it consolidates production and shifts positions elsewhere to ...

Our chief focus for future investments will be: One on increasing our R&D footprint here over time. Second is data and digital.

The U.S. Food and Drug Administration on Wednesday approved a radical new one-time treatment from the Swiss drugmaker, weeks earlier than e...

While this probably won’t help people who are born deaf, scientists are hopeful it will work for patients who lost their hearing at a young...

In collaboration with the Banner Alzheimer's Institute, the Swiss company will study two therapies in cognitively healthy people who are at...